Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Human relevance of NRAS/BRAF mouse melanoma models.

Conde-Perez A, Larue L.

Eur J Cell Biol. 2014 Jan-Feb;93(1-2):82-6. doi: 10.1016/j.ejcb.2013.10.010. Epub 2013 Nov 4. Review.

PMID:
24342721
2.

Comparative analysis of BRAF, NRAS and c-KIT mutation status between tumor tissues and autologous tumor cell-lines of stage III/IV melanoma.

Knol AC, Pandolfino MC, Vallée A, Nguyen F, Lella V, Khammari A, Denis M, Puaux AL, Dréno B.

Exp Dermatol. 2015 Jan;24(1):70-3. doi: 10.1111/exd.12584. Epub 2014 Dec 8.

PMID:
25363723
3.

[Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].

Lázár V.

Magy Onkol. 2013 Jun;57(2):96-9. doi: MagyOnkol.2013.57.2.96. Epub 2013 May 20. Hungarian.

4.

Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma.

Puig-Butillé JA, Badenas C, Ogbah Z, Carrera C, Aguilera P, Malvehy J, Puig S.

Exp Dermatol. 2013 Feb;22(2):148-50. doi: 10.1111/exd.12080.

5.

miR-146a promotes the initiation and progression of melanoma by activating Notch signaling.

Forloni M, Dogra SK, Dong Y, Conte D Jr, Ou J, Zhu LJ, Deng A, Mahalingam M, Green MR, Wajapeyee N.

Elife. 2014 Feb 18;3:e01460. doi: 10.7554/eLife.01460.

6.

KIT, NRAS, BRAF and PTEN mutations in a sample of Swedish patients with acral lentiginous melanoma.

Zebary A, Omholt K, Vassilaki I, Höiom V, Lindén D, Viberg L, Kanter-Lewensohn L, Johansson CH, Hansson J.

J Dermatol Sci. 2013 Dec;72(3):284-9. doi: 10.1016/j.jdermsci.2013.07.013. Epub 2013 Aug 8.

PMID:
23993026
7.

The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.

Ekedahl H, Cirenajwis H, Harbst K, Carneiro A, Nielsen K, Olsson H, Lundgren L, Ingvar C, Jönsson G.

Br J Dermatol. 2013 Nov;169(5):1049-55. doi: 10.1111/bjd.12504.

PMID:
23855428
8.

BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.

García-Casado Z, Traves V, Bañuls J, Niveiro M, Gimeno-Carpio E, Jimenez-Sanchez AI, Moragón M, Onrubia JA, Oliver V, Kumar R, Nagore E.

Br J Dermatol. 2015 Apr;172(4):1128-31. doi: 10.1111/bjd.13521. Epub 2015 Mar 6. No abstract available.

PMID:
25385688
9.

Somatic BRAF and NRAS mutations in familial melanomas with known germline CDKN2A status: a GenoMEL study.

Zebary A, Omholt K, van Doorn R, Ghiorzo P, Harbst K, Hertzman Johansson C, Höiom V, Jönsson G, Pjanova D, Puig S, Scarra GB, Harland M, Olsson H, Egyhazi Brage S, Palmer J, Kanter-Lewensohn L, Vassilaki I, Hayward NK, Newton-Bishop J, Gruis NA, Hansson J; Melanoma Genetics Consortium (GenoMEL).

J Invest Dermatol. 2014 Jan;134(1):287-90. doi: 10.1038/jid.2013.270. Epub 2013 Jun 14. No abstract available.

10.

NRAS mutant melanoma: biological behavior and future strategies for therapeutic management.

Fedorenko IV, Gibney GT, Smalley KS.

Oncogene. 2013 Jun 20;32(25):3009-18. doi: 10.1038/onc.2012.453. Epub 2012 Oct 15. Review.

11.

Towards personalized therapy for patients with malignant melanoma: molecular insights into the biology of BRAF mutations.

Bradish JR, Montironi R, Lopez-Beltran A, Post KM, MacLennan GT, Cheng L.

Future Oncol. 2013 Feb;9(2):245-53. doi: 10.2217/fon.12.179. Review.

PMID:
23414474
12.

Conjunctival melanomas harbor BRAF and NRAS mutations--response.

Griewank KG, Westekemper H, Schilling B, Livingstone E, Schimming T, Sucker A, Hillen U, Steuhl KP, Zimmer L, Schadendorf D.

Clin Cancer Res. 2013 Nov 15;19(22):6331-2. doi: 10.1158/1078-0432.CCR-13-2368. Epub 2013 Oct 29. No abstract available.

13.

Activity of the heat shock protein 90 inhibitor ganetespib in melanoma.

Wu X, Marmarelis ME, Hodi FS.

PLoS One. 2013;8(2):e56134. doi: 10.1371/journal.pone.0056134. Epub 2013 Feb 13.

14.

KIT, NRAS, and BRAF mutations in nail apparatus melanoma.

Dika E, Altimari A, Patrizi A, Gruppioni E, Fiorentino M, Piraccini BM, Misciali C, Barisani A, Fanti PA.

Pigment Cell Melanoma Res. 2013 Sep;26(5):758-60. doi: 10.1111/pcmr.12123. Epub 2013 Jun 20. No abstract available.

PMID:
23782496
15.

KIT, NRAS and BRAF mutations in sinonasal mucosal melanoma: a study of 56 cases.

Zebary A, Jangard M, Omholt K, Ragnarsson-Olding B, Hansson J.

Br J Cancer. 2013 Aug 6;109(3):559-64. doi: 10.1038/bjc.2013.373. Epub 2013 Jul 16.

16.

Pediatric melanoma: the whole (genome) story.

Pappo AS.

Am Soc Clin Oncol Educ Book. 2014:e432-5. doi: 10.14694/EdBook_AM.2014.34.e432. Review.

17.

Conjunctival melanomas harbor BRAF and NRAS mutations--Letter.

Weber JL, Smalley KS, Sondak VK, Gibney GT.

Clin Cancer Res. 2013 Nov 15;19(22):6329-30. doi: 10.1158/1078-0432.CCR-13-2007. Epub 2013 Oct 28. No abstract available.

18.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

19.

GAB2 induces tumor angiogenesis in NRAS-driven melanoma.

Yang Y, Wu J, Demir A, Castillo-Martin M, Melamed RD, Zhang G, Fukunaga-Kanabis M, Perez-Lorenzo R, Zheng B, Silvers DN, Brunner G, Wang S, Rabadan R, Cordon-Cardo C, Celebi JT.

Oncogene. 2013 Aug 1;32(31):3627-37. doi: 10.1038/onc.2012.367. Epub 2012 Aug 27.

20.

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Trunzer K, Pavlick AC, Schuchter L, Gonzalez R, McArthur GA, Hutson TE, Moschos SJ, Flaherty KT, Kim KB, Weber JS, Hersey P, Long GV, Lawrence D, Ott PA, Amaravadi RK, Lewis KD, Puzanov I, Lo RS, Koehler A, Kockx M, Spleiss O, Schell-Steven A, Gilbert HN, Cockey L, Bollag G, Lee RJ, Joe AK, Sosman JA, Ribas A.

J Clin Oncol. 2013 May 10;31(14):1767-74. doi: 10.1200/JCO.2012.44.7888. Epub 2013 Apr 8.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk